Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
B cell maturation antigen
BCMA
CAR-T
Chimeric antigen receptor T cell
MM
Multiple myeloma
Targeted immunotherapy
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
08
11
2018
accepted:
31
12
2018
pubmed:
30
1
2019
medline:
26
3
2019
entrez:
30
1
2019
Statut:
ppublish
Résumé
Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years. However, many therapeutic side effects limit the promotion and clinical use of this novel effective approach such as cytokine release syndrome, antigen escape, and neurotoxicity. We should make every effort to do further study about this immunotherapy to make it safer and effective. This review focusing on this topic clarifies the following contents: present status of MM treatment, effectiveness of CAR-T cells, features of BCMA, preclinical and clinical trials of BCMA CAR-T cells therapy, and existing problems and strategies. Hoping to provide a reference for the subsequent correlative clinical and research.
Identifiants
pubmed: 30693373
doi: 10.1007/s00277-018-03592-9
pii: 10.1007/s00277-018-03592-9
pmc: PMC6423312
doi:
Substances chimiques
B-Cell Maturation Antigen
0
Neoplasm Proteins
0
Receptors, Chimeric Antigen
0
TNFRSF17 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-822Subventions
Organisme : the Shaanxi province science and technology research projects
ID : 2016SF-122
Organisme : the First Affiliated Hospital of Xi?an Jiaotong University clinic research projects
ID : XJTU1AHCR2014-032
Références
EMBO J. 1992 Nov;11(11):3897-904
pubmed: 1396583
J Exp Med. 2004 Jan 5;199(1):91-8
pubmed: 14707116
Blood. 2005 May 15;105(10):3945-50
pubmed: 15692072
J Immunol. 2007 May 1;178(9):5612-22
pubmed: 17442944
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
J Immunol. 2007 Dec 1;179(11):7276-86
pubmed: 18025170
Leukemia. 2008 Feb;22(2):406-13
pubmed: 18046446
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Br J Cancer. 2009 Oct 6;101(7):1051-8
pubmed: 19789533
Leukemia. 2010 Jun;24(6):1160-70
pubmed: 20428207
Immunol Rev. 2010 Jul;236:139-50
pubmed: 20636814
Hematology Am Soc Hematol Educ Program. 2010;2010:303-9
pubmed: 21239810
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Clin Cancer Res. 2011 Mar 15;17(6):1264-77
pubmed: 21411442
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
J Clin Invest. 2012 Oct;122(10):3456-63
pubmed: 23023717
Clin Cancer Res. 2013 Apr 15;19(8):2048-60
pubmed: 23344265
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Blood. 2014 Jan 2;123(1):61-9
pubmed: 24162716
Nat Commun. 2014;5:2997
pubmed: 24429703
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Nat Rev Clin Oncol. 2015 Jan;12(1):42-54
pubmed: 25421279
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
Crit Rev Oncol Hematol. 2015 Dec;96(3):399-412
pubmed: 26153389
Immunotherapy. 2015;7(11):1187-99
pubmed: 26370838
Blood Rev. 2016 May;30(3):157-67
pubmed: 26574053
Annu Rev Pharmacol Toxicol. 2016;56:59-83
pubmed: 26738472
Br J Haematol. 2016 Mar;172(5):685-98
pubmed: 26791002
Biochem Soc Trans. 2016 Apr 15;44(2):397-405
pubmed: 27068946
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Leukemia. 2016 Nov;30(11):2208-2213
pubmed: 27211270
Am J Hematol. 2016 Jul;91(7):719-34
pubmed: 27291302
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Leukemia. 2017 Feb;31(2):382-392
pubmed: 27479184
Nat Rev Cancer. 2016 Aug 23;16(9):566-81
pubmed: 27550819
Br J Haematol. 2016 Nov;175(3):366
pubmed: 27612286
Int J Mol Sci. 2016 Sep 08;17(9):
pubmed: 27618026
PLoS One. 2016 Dec 1;11(12):e0166891
pubmed: 27907031
Clin Exp Med. 2017 Nov;17(4):431-439
pubmed: 28120217
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125
pubmed: 28233151
Mol Ther Methods Clin Dev. 2017 Jan 10;4:192-203
pubmed: 28345004
Br J Haematol. 2018 Jun;181(5):689-692
pubmed: 28369673
Cancer Treat Rev. 2017 Apr;55:190-199
pubmed: 28431262
Am Soc Clin Oncol Educ Book. 2017;37:561-568
pubmed: 28561703
Leuk Res. 2017 Aug;59:75-84
pubmed: 28582636
Leuk Res. 2017 Sep;60:63-73
pubmed: 28756350
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Blood. 2017 Dec 14;130(24):2594-2602
pubmed: 28928126
Leukemia. 2018 Feb;32(2):402-412
pubmed: 28951562
Blood. 2018 Feb 15;131(7):746-758
pubmed: 29284597
Cancer. 2018 May 15;124(10):2075-2085
pubmed: 29409124
Immunotherapy. 2018 Feb 1;10(4):265-282
pubmed: 29421983
Ann Hematol. 2018 Jun;97(6):925-944
pubmed: 29500711
Leuk Res. 2018 May;68:90-97
pubmed: 29579627
Hum Gene Ther. 2018 May;29(5):585-601
pubmed: 29641319
Mol Ther. 2018 Jun 6;26(6):1447-1456
pubmed: 29678657
Ann Hematol. 2018 Aug;97(8):1327-1335
pubmed: 29766234
Nucleic Acids Res. 1994 Apr 11;22(7):1147-54
pubmed: 8165126
Int Immunol. 1998 Nov;10(11):1693-702
pubmed: 9846698